Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...
A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma. This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Minimal Residual Disease (MRD) Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...
Patients with stage 3 colorectal cancer who tested MRD-positive with Signatera after surgery saw a meaningful survival ...
A multiple myeloma survivor discusses how continued minimal residual disease negativity made her feel more confident in coming off of maintenance therapy. After undergoing treatment — including a stem ...
Hosted on MSN
Adaptive Biotechnologies targets $1,300 ASP for MRD tests in 2025 driven by pricing improvements
CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year. Key drivers included a higher gapfill rate of $2,007 for the clonoSEQ test ...
Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and ...
SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback